Theresa Babuscio

Theresa Babuscio

Auto-generated profile, based on publicly available information

Theresa Babuscio

Yale School of Medicine, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Journal of Substance Use and Addiction Treatment
Verified
Journal Article
Closed access
AJAyana Jordan
Ayana Jordan
MCMark Costa
Mark Costa
CNCharla Nich
Charla Nich
MSMargaret Swarbrick
Margaret Swarbrick
TBTheresa Babuscio
Theresa Babuscio
CBChyrell Bellamy
Chyrell Bellamy

25 February 2022 in Drug and Alcohol Dependence Reports
Verified
Journal Article
Open access
EDElise E. DeVito
Elise E. DeVito
JPJames Poling
James Poling
TBTheresa Babuscio
Theresa Babuscio
CNCharla Nich
Charla Nich
KCKathleen M. Carroll
Kathleen M. Carroll
MSMehmet Sofuoglu
Mehmet Sofuoglu
Introduction: There are no approved medications for the treatment of cocaine use disorder (CUD). Modafinil, a cognitive-enhancer with weak stimulant-like effects, has shown promise in initial studies as a treatment for CUD. Its potential efficacy has not been examined in individuals dually dependent on cocaine and opioids.Methods: This study examined the efficacy of modafinil, in combination with contingency management (CM), for reducing cocaine and opioid use and improving cognitive function in methadone-stabilized individuals with opioid and cocaine dependence. We conducted a 17-week, double-blind, randomized controlled trial in which participants were randomized to one of four conditions: 1) modafinil + CM; 2) modafinil + yoked-control (YC); 3) placebo + CM; or 4) placebo + YC. Additionally, all subjects received platform treatments of cognitive behavioral therapy (CBT) and methadone. While the original planned sample size was N = 160, a total of 91 participants were randomized. The two primary cocaine use outcomes were percentage of urine specimens positive for cocaine and percent of days of self-reported abstinence from cocaine during treatment. Cognitive function, opioid use, and secondary cocaine use outcomes were also considered. Results: Modafinil was well-tolerated with minimal reports of adverse effects. Modafinil was no more effective than placebo in reducing cocaine or opioid use or improving cognitive performance.Conclusions: In the context of a trial with robust control conditions and platform treatments, these findings did not provide support for the efficacy of modafinil treatment for the treatment of CUD in methadone-stabilized individuals with dual opioid and cocaine dependence.